Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMWYNN1)

Drug Name	CBP-201 DMWYNN1
Drug Type	Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

1 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Atopic dermatitis	DISTCP41	EA80	Phase 3	[1]
------------------------------------------------------------------------------------

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Asthma	DISW9QNS	CA23	Phase 2	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05614817) A Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of CBP-201 Monotherapy in Patients With Moderate-To-Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT04773678) A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Efficacy and Safety Study of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation. U.S.National Institutes of Health.